Lights and Shadows about the Effectiveness of IVF in HIV Infected Women: A Systematic Review

Table 1

Summary of the published studies on fresh nondonor oocyte IVF/ICSI cycles in serodiscordant couples with an HIV infected female partner and baseline characteristics of study and control groups.

Study	Type of study	Treatment cycles/couples ()	Control group	Mean female age	Body Mass Index		⁢Tubal disease (%)		Markers of ovarian reserve
Ohl et al. 2003 [14]	Clinical prospective	12/9	49 cycles; HIV noninfected women with HIV infected male partners	35.9	Study; NM	Control; NM	Study; NM	Control; NM	Study; Day 3 FSH = 9 IU/L	Control; Day 3 FSH = 7 IU/L
Ohl et al. 2005 [15]	Clinical prospective	62/50	NA	35	NM	NA	32%	NA	Day 3 FSH = 7.1 IU/L	NA
Terriou et al. 2005 [16]	Age-matched cohort	66/29	66 age-matched cycles; HIV noninfected women undergoing ICSI during the same period	35.8	NM	NM	30%	18%	Day 3 FSH = 7.4 IU/L	Day 3 FSH = 7.3 IU/L
Coll et al. 2006 [17]	Age-matched cohort	50/35	100 age-matched cycles; HIV noninfected women with HIV noninfected male	NM	NM	NM	NM	NM	NM	NM
Martinet et al. 2006 [18]	Retrospective case-matched control	27/27	77 cycles; HIV noninfected women matched for age, etiology and duration of infertility, history of pelvic surgery, and type of pituitary inhibition	35.5	NM	NM	70.8%	68.83%	NM	NM
Manigart et al. 2006 [19]	Prospective cohort	56/33	62 cycles; Non-HIV infected women with HIV infected male partners	35.6	NM	NM	NM	NM	NM	NM
Douglas et al. 2009 [20]	Retrospective age-matched cohort	29/14	42 age-matched cycles; HIV noninfected women undergoing ICSI for male factor infertility	36.5	NM	NM	35%	NM	Day 2 FSH = 7.7 IU/L	Day 2 FSH = 6.9 IU/L
Prisant et al. 2010 [21]	Retrospective case-matched control	94/52	94 cycles; HIV noninfected women matched for age, etiology of infertility, rank of oocyte retrieval, and type of ART	34.7	NM	NM	NM	NM	NM	NM
Santulli et al. 2011 [22]	Prospective age-matched cohort	57/57	171 age-matched cycles; HIV noninfected women with HIV noninfected male partners	34.2	24.2	22.9	Unilateral defect 8%; Bilateral defect 54%	4,6%; 25.2%	Day 3 FSH 6.5 IU/L; AFC: 12.9	Day 3 FSH 7.1 IU/L; AFC 13.9
Nurudeen et al. 2013 [23]	Retrospective age-matched cohort	<35 y: 8; ≥35 y: 52/36	8 age-matched cycles; 52 age-matched cycles; HIV noninfected controls undergoing treatment for male factor infertility	37.7	<35 y: 21; ≥35 y: 28	24.4; 24.7	<35 y: 43%; ≥35 y: 32%	20%; 0%	<35 y: FSH = 6.8 IU/L; AMH: NM; ≥35 y: FSH = 8.5 IU/L; AMH: 0.92 ng/mL	<35 y: FSH = 5.3 IU/L; AMH: NM; ≥35 y: FSH = 7.7 IU/L; AMH: 0.6 ng/mL

value < 0.05. NA: not available. NM: not mentioned.